RT Journal Article
SR Electronic
T1 Oral Colostrum Macrophage-activating Factor for Serious Infection and Chronic Fatigue Syndrome: Three Case Reports
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4545
OP 4549
VO 35
IS 8
A1 TOSHIO INUI
A1 KENTARO KUBO
A1 DAISUKE KUCHIIKE
A1 YOSHIHIRO UTO
A1 TAKAHITO NISHIKATA
A1 NORIHIRO SAKAMOTO
A1 MARTIN METTE
YR 2015
UL http://ar.iiarjournals.org/content/35/8/4545.abstract
AB Background: Gc protein-derived macrophage-activating factor (GcMAF) immunotherapy has been steadily advancing over the last two decades. Oral colostrum macrophage-activating factor (MAF) produced from bovine colostrum has shown high macrophage phagocytic activity. GcMAF-based immunotherapy has a wide application for use in treating many diseases via macrophage activation or for use as supportive therapy. Results: Three case studies demonstrate that oral colostrum MAF can be used for serious infection and chronic fatigue syndrome (CFS) without adverse effects. Conclusion: We demonstrate that colostrum MAF shows promising clinical results in patients with infectious diseases and for symptoms of fatigue, which is common in many chronic diseases.